1

KYROBIO is a European Commison Framework 7 supported project. This first edition of the newsletter aims to provide an introduction to the project consortium and research themes highlighting novel research and innovative technology developments from within the project.

“The discovery, development and demonstration of biocatalysts for use in the industrial synthesis of chiral chemicals.”

The global speciality chemicals market is set to grow to over $600bn by 2016 [1], with the global market for generic drugs projected to reach over $129bn by 2014 [2]. However, despite this growth, there are still tough challenges for the sector including the rising cost of raw materials, increased regulatory control and growing environmental awareness as society demands ‘greener’ options for chemical manufacture. Industrial Biotechnology, defined as: ‘The use of biological substances for the processing and production of enzymes, chemicals, materials and energy’, is increasingly becoming a means of addressing these challenges. Its utilisation has associated benefits of reduced use of organic solvents, toxic

Edition 1, May 2012

metals and reaction temperatures, normally associated with traditional chemocatalysts. KYROBIO aims to exploit this technology to make advances in the industrial synthesis of chiral compounds.

Chirally pure compounds are an important class of chemicals, as they have increased reactivity within applications such as pharmaceuticals and nutraceuticals. The use of industrial biotechnology for the production of chiral chemicals has already shown great potential, competing with traditional chemocatalysts, through specific targeted synthesis of the enantiomer of choice, thus increasing the total production yield of product. Although many chiral compounds are now synthesised using biocatalysis the technology behind such processes still has gaps within its capabilities, when compared to the breadth of chemocatalysis.

KYROBIO will use an SME focused approach to address the industrial need for chiral synthesis via biocatalysis, using necessary supporting technologies. Moreover, the SMEs will also have the potential to exploit the added value from biocatalysis throughout the scope of the project and beyond. This will

lead to demonstration of greener processes, to implementing the technology for the next generation of chiral producing biocatalysts, resulting in new economically viable industrial production process.

With a total budget of €7.8M, over 4 years, the research objectives for KYROBIO include:

• Broadening the toolbox of single enantiomer chiral chemicals that are produced in Europe by biocatalytic routes.

• The production of lyase enzymes to selectively synthesise molecules with multiple chiral centres applying enzymatic carbon-carbon and carbon-nitrogen bond formation as key technical platforms.

• The selection and development of modified micro-organisms for the production of chemicals and enzymes that have desired properties for industrial application.

• The use of a range of molecular modelling techniques to predict stereo-chemical reactions and provide insight into reaction pathways for potential substrates

2

University of Groningen, Netherlands

The University of Stuttgart, Germany

Technical University of Denmark, Denmark

Chemistry Innovation Ltd, UK

and suggest enzyme modifications with the view to increasing selectivity.

• Scale up and feasibility studies are a main theme within the project as promising candidate chemicals will be commercialised within three years of the completion of the project.

[1] chemicals-technology.com/news/news112581.html

[2] imap/com/imap/media/resources/IMAP_PharmaReport_8_272B8752E0FB2.pdf

A superdisciplinary approach, with the integration of chemistry, molecular biology, enzymology, microbiology, fermentation science, bioengineering and process development will be employed to achieve these objectives. Collaboration between industry and European Centres of Excellence will build long lasting relationships that will enhance European Industrial Biotechnology well beyond the lifetime of the project. The primary objective of the project being to develop routes to synthesise these chemical targets and to produce and apply biocatalysts to expand the practical chiral biocatalytic toolbox and demonstrate overall superiority when compared to traditional chemocatalysts.

www.KYROBIO.EU

C-Tech Innovation Limited, UK

Evocatal GmbH, Germany

BICT srl, Italy

Ingenza Limited, UK

CLEA Technologies BV, Netherlands

BioInfoBank Institute, Poland

Prozomix Limited, UK

VTU Technology GmbH, Austria

X-Zyme GmbH, Germany

Bio-Prodict BV, Netherlands

ACIB GmbH, Austria

The University of Graz, Austria

The University of Manchester, UK

Co-ordinated by C-Tech Innovation Limited, the KYROBIO project consortium consists of 17 partners from 7 European countries:

3

Contents 1. An Introduction to KYROBIO2. KYROBIO Partners4. KYROBIO, The Beginning5. KYROBIO News 6. Meet The Partners 10. New Consortium Members11. In The Press

4

“I love the challenge of interdisciplinary research. It offers so many opportunities for the individual to expand their knowledge and develop a greater appreciation of the contribution of several disciplines to the achievement of research goals. I believe the KYROBIO project exemplifies this perfectly, and I am looking forward to working with all the project participants for the next 4 years. KYROBIO is a highly ambitious project and can make a real impact delivering new knowledge and products; making a competitive advantage for European industry; and providing opportunities to promote biotechnology as a part of the greater Knowledge Based Bio Economy for Europe”... Kay McClean.

KYROBIO consortium, at the kick off meeting to the project in Brussels Jan 2102

KYROBIO,The BeginningBy John Whittall, CoEBio3 & Kay McClean, C-Tech Innovation

The initial KYROBIO project was conceived and constructed in CoEBio3 Manchester by Dr. John Whittall as part of the centres industrial support activities for UK SMEs. As this call was targeted at SMEs the needs of a group of UK and European SMEs with ambitions to develop chiral chemistry for the market place and those that could develop the supporting technologies to implement these activities were identified. This was then enhanced by leading groups of Europe’s academic researchers in biotechnology for multiple centre chiral chemistry application (with industrial market sector targets) to make a balanced program. John’s role within CoEBio3 is Research Exploitation Manager and has to identify technical opportunities arising from the biocatalytic research and act as an industrial/academic interface. He also coordinates the FP7 programmes. John previously worked for Stylacats as Head of Research and before that Lancaster Synthesis. The Project Manager of KYROBIO is Dr. Kay McClean who took a leading role in managing the writing of the application and negotiation of the final contract. The role of C-Tech Innovation Ltd (UK-based SME) as the lead partner exemplifies the important roles assigned to SMEs in the delivery of the KYROBIO project.

5

Hands-on Pichia Course: From Idea to Protein Products

The hands-on Pichia course, February 2012, was run by the acib to explain and demonstrate the opportunities for efficiently using the Pichia expression system. As a pre-programme to the Pichia 2012 conference the course aimed to explore the underlying concepts and deliver insight into current laboratory practice. A number of Pichia’s special features were addressed to highlight how its full molecular capacity can be exploited. The course was fully booked, attended by participants from 15 nations, and a great success. Below Tanja Hajek, Scientific Co-ordinator at acib, tells how the course ran.

Hands-on Pichia pastoris by Tanja Hajek, acib

“From the Idea to the Project” was the slogan of the first hands-on course on February 26th to 29th in Graz. “The interest for the forerunner to the Pichia 2012 conference in Alpbach exceeded all our expectations”, said Anton Glieder, CSO of acib. 33 participants from 15 nations (Argentina, Canada, South Korea, France, Poland, Italy, Slovenia, Denmark, Finland, Holland, Germany, Ireland, UK, Switzerland, Austria) attended a three day highly professional lab course serviced by 17 Pichia-specialists from acib, TU Graz and University of Natural Resources and Life Sciences, Vienna (BOKU) as well as from the University of Applied Sciences, Wädenswil, Switzerland.

3DM systems are protein super-family platforms that are a collection, connection and integration of many different types of protein super-family data. 3DM systems can be used to determine the function of individual amino acids and to predict the effects of mutations. Two others are in the pipeline. Once set up Bio-Prodict will be running 3DM introduction courses in order for the KYROBIO partners to better understand and utilise the systems.

Henk-Jan Joosten visited Ingenza Ltd on April 25th 2012 for the first part in formal training on the use of 3DM databases. Three Ingenza staff were trained (Reuben Carr, Franck Escalettes and Ian Archer) and a further 2 employees have since begun practising using the database. Ingenza have one superfamily database already built and have ordered the next one.

Conference on Multistep Enzyme-Catalysed Processes (MECP) 2012

The MECP12 took place in Graz from April 10th-13th 2012. It was co-organised by The University of Graz, Graz University of Technology and the Austrian Centre of Industrial Biotechnology (acib). More than 150 scientists, including some KYROBIO partners, from all five continents attended the meeting with its 11 invited lectures and 24 oral presentations. From the 68 poster presentations three posters were awarded, although the jury assured that it was a tremendously hard decision, since the quality was extremely high.

KYROBIO Update / NewsKYROBIO started in December 2011 with the first consortium kick off meeting in early January 2012 at The Hotel Leopold, Brussels. This meeting was attended by all of the consortium as well as Maria Fernandez-Guiterrez and Marco Cortopassi from the European Commission.

There was a great air of enthusiasm for the start of the project. For some partners it was the first time meeting other members of the consortium, but for others it was a chance to reunite with colleagues where collaborations had already been forged. Existing collaborations will grow and new ones created amongst the partners as the consortium take its first steps towards success, goals and deliverables of the project.

The sixth month consortium meeting took place in May 2012, hosted by Christine Klug and colleagues at The University of Stuttgart. The meeting took place over two days with a general consortium meeting on the first day and the second day being used for more detailed technical discussions amongst work packages. The meeting was a great opportunity for the consortium to share achievements network and share ideas for forthcoming research activities.

Bio-Prodict – 3DM systems

Dr. Henk-Jan Joosten, CEO Bio-Prodict has announced that Bio-Prodict has now completed two 3DM database systems:

- The cupin superfamily database- The PLP dependent transferase superfamily database. KYROBIO partners (L-R) Mandana Gruber,

Nick Turner & John Whitall enjoying the MECO12 conference

6

The organisation of this training course was supported by the FP7 project KYROBIO. Scientists from five KYROBIO partners attended the course.

The program was comprehensive and demanding. In the beginning the attendants gained the skills necessary to decide between different available host strains, vectors and other elements of the available Pichia expression systems. In a first step they learned to understand the product-process-development from strain construction to cultivation. The session “Physiology & Screening of Production Strains“ dealt with the importance of screening in the development of high-level Pichia production strains and with the usage of the best screening setups for different phenotypes and promoters. Finally the participants learned how to design a suitable strategy to produce a desired target product and to choose the appropriate molecular design.

For the participants it was great to exchange experiences and to profit from the knowledge of other attendees and the acib-crew – all in a relaxed working atmosphere. “I visited several hands on courses yet, but the professional approach at this course was outstanding“, as Alfred Engel (Roche) stated at the end of three days, with the comprehensive knowledge about the use of the yeast Pichia pastoris. “For acib it was also a unique opportunity to demonstrate the competence and integrated knowledge of our acib research groups on Pichia“ stated Diethard Mattanovich, acib area leader for “Cell Design and Engineering” and Professor at BOKU, Vienna.

Meet the partnersThis section of the newsletter will introduce some of the partners working on the KYROBIO project around Europe.

BiCT srl

BiCT expertise ranges from molecular biology heterologous expression, purification and immobilization of biocatalysts for selective biotransformation. The main company goal is to provide cost-effective and industrial scale biocatalysts and bioprocesses, tailoring them on a client specific basis. A tight cooperation with Resindion srl, a subsidiary of Mitsubishi Chemicals Corporation producing chromatography and enzyme carrier resins, has enabled the BiCT technology on biocatalysis to be applied in several processes in different fields (from food to pharma, from nutraceutics to cosmetics).

The main role of BiCT in the KYROBIO project is involved in enzyme immobilization, establishing a screening platform able to perform multiple immobilization trails. For this purpose, BiCT will develop and functionalize resins, to increase the

Top photo: Participants at the Hands-on Pichia course Feb 2012. Middle and bottom: In the laboratory at the Hands-on Pichia course

possibility of a high performance and stable immobilized biocatalysis. The target enzymes will consist mainly in omega-transaminases in collaboration with Ingenza Ltd. Furthermore, working with C-Tech Innovation, engineering strategies and systems to adapt and maximize the use of immobilized enzymes on industrial scale processes will be developed.

Meet BiCT members:

Dr. Roberto Verga – CEO and Business Development Manager.

Roberto has twenty years of experience in Big Pharma, leading industrial projects regarding

enzymatic biotransformation and production of recombinant proteins in several hosts, from bacteria to mammalian and plant cells. At BiCT he supervises biotechnological processes, focusing on the downstream phases, purification and immobilization of biocatalysts. He has several publications in peer reviewed journals and two patents in biocatalysis applied to bulk pharma API production.

VTU Technology

VTU Technology is an Austrian Life Sciences SME which focuses on expression strain and process development for the production of enzymes for biocatalysis, as well as other applications, and the production of diagnostic and therapeutic proteins based on expression in Pichia pastoris. The core component of VTU´s expression system is a library of yeast promoters – co-developed with Graz University of Technology – enabling the targeted optimization of

7

in 2008, and are the project representatives of in KYROBIO.

Roland Weis, Head of Operations, completed his M.Sc. in microbiology at Karl-Franzens-University Graz and holds a Ph.D. in molecular biotechnology from Graz University of

Technology. After his engagement in a bilateral project with Pasadena-based BioCatalytics Inc., he was appointed authorized representative and scientific director of BioCatalytics Europe GmbH, Austria. In 2007, he joined VTU to head the operational team for high throughput protein production with Pichia pastoris.

Thomas Purkarthofer, Head of Business Development, joined VTU in 2006 managing the start-up of the company´s new Protein Technologies Unit. He is responsible

for the commercialization of VTU´s proprietary Pichia pastoris protein expression platform and global

high-level yeast protein expression for a given target protein. VTU´s expertise comprises streamlined laboratory procedures and profound know-how of a skilled research team in molecular biotechnology of yeast, cultivation and high-throughput screening, bioreactor cultivation and downstream processing, the application of enzymes for biocatalysis and protein/enzyme analytics.

The main task of VTU Technology in the KYROBIO project is the generation of Pichia pastoris protein expression strains and corresponding fermentation protocols. This activity will be following acib work on enzyme discovery and development and conducted in close collaboration with acib. VTU will apply its in-house routines for time-saving screening and expression strain generation. In addition, after selection of productive clones identified in screening, VTU will elaborate efficient enzyme production procedures and will provide these enzymes for other participants in this project.

Meet VTU members:

Thomas Purkarthofer and Roland Weis, are main members of the senior management team of VTU Technology since its foundation

8

Chemistry Innovation KTN

Chemistry Innovation Knowledge Transfer Network (CI KTN) is funded by the UK government as a Knowledge Transfer Network. Its main aim is to help the chemistry-using industries in the UK to access, from a single source, the knowledge base in science, engineering and manufacturing, thereby enabling those industries to innovate successfully. It is not limited to the traditional chemical industry and covers any sector which uses chemistry and spans materials, biotechnology, home and personal care, food and other industries which rely on chemistry in some aspect of their business. A current major challenge enabling businesses to understand the implications of renewable feedstocks and industrial biotechnology, stimulating companies to innovate in bio based products. Dissemination is one of its key skills and as such are taking on the role of dissemination in the KYROBIO project.

Meet CI KTN members:

Dr. Katie Nickson has a PhD in Biomaterials and Medical Devices from the University of Liverpool and within Chemistry Innovation is responsible for delivering the bio-

based product priority to the chemistry and chemistry-using industries. She is taking lead on the dissemination of the KYROBIO project having experience in the translation of technical sector to the non-specialist in the field at many levels.

Tom van den Bergh finished his bachelor’s in bioinformatics in 2007 at the applied University of Leiden and in 2010 received his Master’s degree bioinformatics at

the Wageningen University. During his studies Tom has worked on the 3DM system which formed the basis of Bio-Prodict’s start-up in 2008. For his master thesis Tom created a mutation database for Fabry’s disease, caused by mutations in a human alpha amylase family member, this mutation database was published in Human Genetics. Tom has been working for Bio-Prodict since March 2010.

Remko Kuipers obtained his bachelor in Information and Communication Technology with specialization software development at the Avans

Institute of Professional Education in Hertogenbosch in 2005. His internship was done at the Laboratory of Fungal Genomics, Wageningen University where he was involved in the initial design and development of the 3DM platform. He obtained a masters degree in Bio-Informatics at the University of Wageningen in 2007. For his MSc thesis Remko joined the CMBI group of Prof. Vriend at the Radboud University in Nijmegen for a project focused on using webservices to assemble protein superfamilies. He has remained involved in 3DM since its inception, and has been employed by Bio-Prodict since 2009.

customer relations. Thomas received his Ph.D. in chemistry from Graz University of Technology and was engaged in and managed several industrial biocatalysis R&D projects.

Bio-Prodict

Bio-Prodict, a spin-off company of the Wageningen University, specialising in bio-informatics related services. The main focus of Bio-Prodict is data mining, storage and analysis of protein (super-family) data. Bio-Prodict has developed 3DM, a tool that can automatically generate super-family specific databases designed to guide scientific research in the field of protein engineering, drug design and DNA-diagnostics. These systems have proven to be powerful tools for the understanding of different protein features and the prediction of effects of mutations.

Meet Bio-Prodict Members:

Henk-Jan Joosten is a founder of Bio-Prodict. He holds masters degree in bio-informatics from the Centre of Molecular and Bio-molecular Informatics (CMBI) where he worked

on the generation of a protein super-family database for the nuclear receptor super-family then completed his PhD in 2006 at the Wageningen University where he developed 3DM. He continued the development of 3DM during a post-doctoral period till December 2007. From the start of 2008 he focused on the foundation of Bio-Prodict resulting in the start-up in May 2008.

9

Design and Engineering, Bioprocess Engineering, Metabolic Modeling and Synthetic Biology.

Within KYROBIO acib manages work package 4 that deals with “Fermentation Science for Novel Enzymes and Improved Fermentation Strains”. acib scientists improve expression systems and fermentation conditions for producing hydroxynitrile lyases and transaminases. The discovery, characterization and improvement of the enzymes are tasks with acib participation in work packages 1, 2 and 3. acib is also involved in training activities of KYROBIO and has organized the first “Hands-on Pichia lab course”.

Meet acib Members:

Andrea Camattari obtained his PhD in industrial biotechnology at University of Milano-Bicocca (Italy) in 2006. He joined the acib in 2010 before he accepted a position as assistant professor at the Graz University of Technology in 2011. He supervises the studies of Thomas Vogl for the development of new Pichia promoters.

Anton Glieder is scientific director of the non-profit research centre acib and professor for Biotechnology. He has a successful track record of industrial collaboration, EU FP project management and innovations in biocatalysis and synthetic biology. In KYROBIO he is leader of work package 4.

Mandana Gruber obtained her PhD at Graz University of Technology. She is research scientist and project manager at acib. At KYROBIO she is responsible for coordination and management of the acib and

Innovation. She has experience using continuous flow equipment to carry out high value biotransformation reactions, and has coordinated the scale up of such reactions in flow reactors to pre-pilot scale. Sally will carry out the technical work in work package 6 of the KYROBIO project.

Dr Kay McClean’s technical background is in Microbiology. After studying in Ireland she carried out research in microbial physiology and genetics at universities in the

UK, The Netherlands and Ireland. For the past decade she has been based in the UK and has specialised in biocatalysis, firstly at Stylacats Ltd and latterly at C- Tech Innovation were she has been a Project Manager working on national and international projects for the last 6 years.

The Austrian Centre of Industrial biotechnology (acib)

acib is a competence centre linking the scientific and technological expertise of seven universities and about 30 company partners, among them well known companies as BASF, DSM, Sandoz, Boehringer Ingelheim RCV, Lonza, and F.Hoffmann-LaRoche. Applying and adapting the tools and concepts of nature for industrial production acib translates basic academic research to industrial implementations by our industrial partners.

Over 180 acib researchers are active in more than 30 scientific projects. The main research fields are Biocatalytic Synthesis, Enzymes and Polymers, Cell Design and Engineering, Protein

Left to right: 2nd row: Andrea Camattari, Helmut Schwab, Margit Winkler, Kerstin Steiner, Toni Glieder, Thomas Vogl. 1st row: Ingund Anderl, Elisa Lanfranchi, Mandana Gruber, Tanja Hajek

C-Tech Innovation

C-Tech Innovation is a leading UK based, internationally focused, innovation management and technology development company. C-Tech Innovation’s in-house research group develops new products and technologies in collaboration with external partners both from academia and industry. Activities in biotechnology focus on process design and scale up enabling higher quality products to be produced in vastly shortened time. Recent projects have focussed on the use of biocatalytic oxidase and transaminase based reactions to prepare functionalised chiral amines and amino acids.

Meet C-Tech Innovation Members:

Edward Jones has a degree in Chemistry (MChem) from University of Durham and is currently a Project Manager at C-Tech Innovation. He is responsible for the management of

large European FP7 and TSB projects and he has experience carrying out high value biotransformations and experience using continuous flow reactor technology. He will lead the technical work for the KYROBIO project within C-Tech Innovations work package responsibilities.

Sally Housden has a degree in Chemistry (MChem) from University of Sheffield and is currently a Research Chemist at C-Tech

Margit Winkler is Senior Researcher at the acib and lecturer at Graz University of Technology. In the KYROBIO project, she is working on hydroxynitrile lyases and transaminases from plants together with Elisa Lanfranchi.

New Consortium Members – Welcome

This section is to highlight and welcome new members to the consortium.

Eva-Maria Fischereder has started her PhD at the University of Graz on the KYROBIO project on in March 2012.

“I am currently working on my

PhD-thesis within the KYROBIO project under the supervision of Prof. Wolfgang Kroutil. My research focuses on the enzyme family Pictet Spenglerases which are involved in the biocatalytic synthesis of isoquinoline derivatives. I first got in contact with biocatalysis in 2009 during my bachelor thesis at the department of organic and bioorganic chemistry. Hence the combination of organic synthesis and bioorganic working techniques emerged as very interesting for me, I decided to work as a summer student in the following year. During this time Prof. Kroutil offered me a master thesis, working with the promising berberine bridge enzyme”.

10

Elisa Lanfranchi is the new member of KYROBIO project at the acib and is a PhD student.

“My name is Elisa Lanfranchi and I come from Italy. I graduated

in February 2011 in Industrial Biotechnology at University of Milano-Bicocca. Throughout my university career I was interested in biotechnology research. Last September I came to Graz for the internship at the Institute of Molecular Biotechnology in Glieder’s Group. I enjoy me stay in Austria that is why I decided to live here and start my PhD in acib in Margit Winkler’s Group.”

Dr. Stefano Zucchinali is a new member the KYBRIOBIO project at BiCT, where he is a Research Scientist.

Stefano joined BiCT, in 2011,

immediately after gaining his master degree in Industrial Biotechnology at Milan University. After an intensive training in enzyme immobilization techniques and biocatalysis, he supported actively the research and development linked to the formulation of several commercial immobilized enzymes and the synthesis of innovative carriers at this purpose.

TU-Graz team next to preparative scale transformations of novel HNLs developed during the project.

Tanja Hajek studied microbiology at the University of Graz. Within acib she is responsible for the Scientific Coordination and was therefore involved in the application of KYROBIO and several other EU projects; within KYROBIO she is responsible for local coordination, finances and events.

Helmut Schwab became professor of molecular biotechnology at Graz University of Technology in 2003. In addition he was key researcher of the Research Centre Applied Biocatalysis. At acib he is responsible for the research area “Protein Design and Engineering” and by this means contributes to the KYROBIO program. He also supervises a PhD student at TU Graz for the development of new bacterial HNLs.

Kerstin Steiner obtained her PhD from the Centre of NanoBiotechnology at the University of Applied Life Sciences and Natural Resources Vienna in 2006. Since June 2010 she is senior scientist at acib. One focus of her research is the investigation and engineering of HNLs with a new fold.

Thomas Vogl studied molecular microbiology at the University of Graz. Currently he works on his PhD thesis at the Graz University of Technology. In frame of the KYROBIO project, he is investigating transcriptional regulation in Pichia pastoris and the development of new synthetic promoters to improve and facilitate protein production.

Romana Wiedner finished her PhD thesis at the Institute of Molecular Biotechnology at the Graz University of Technology in December 2007. After maternity leave she is back at acib since November 2011. Within the EU project KYROBIO she is working as a research scientist identifying new bacterial HNLs.

11

In PressBelow is a list of articles currently in press that are related to the research areas undertaken within the KYROBIO project.

1. Henderson R.K., Jimenez-Gonzalez .C, Preston C., Constable D.J.C. & Woodley J.M., 2008. EHS & LCA Assessment for 7-ACA Synthesis. A case study for comparing biocatalytic and chemical synthesis. Industrial Biotechnology; 4(2); 180-192.

2. Tufvesson P., Fu W., Jensen J.S. & Woodley J.M., 2010. Process consideration for the scale up and implementation of biocatalysis. Food & Bioproducts Processing; 88; 3-11.

3. Tufvesson P., Lima-Ramos J., Jensen J.S., Al-Haque N., Neto W. & Woodley J.M., 2001. REVEIW. Process considerations for the asymmetric synthesis of chiral amines using transaminases. Biotechnology & Bioengineering; 108 (7); 1479-1493.

4. Tufvesson P., Lima-Ramos J., Norbold M. & Woodley J.M., 2011. Guidelines and cost analysis for catalyst production for biocatalytic processes. Organic Process Research & Development; 15; 226-274.

5. van Leewan J.G.E., Wijma H.J., Floor R.J., van der Laan J.M. & Janssen D.B., 2012. Direct evaluation strategies for enantiocomplementary haloalkane dehalogenases: from chemical waste to enantiopure building blocks. ChemBioChem; 13; 137-148.

6. Wu B., Szymanski W., Wybenga G.G., Herbeling M.W., Bartsch S., de Wildeman S., Poelarends G.J., Feringa B.C. & Janssen D.B., 2012. Mechanism-inspired engineering of phenylalanine aminomutase for enhanced β-regioselective asymmetric animation of cinnamates. Angewandle Chemie International Edition; 51; 482-486.

www.KYROBIO.euThis project is financially supported by the 7th framework programme of the European Commission under the grant agreement number 289646

To have a featured article in the next edition contact Katie Nickson; katienickson@ciktn.co.uk

Designed in-house @ Chemistry Innovation. Printed on FSC certified paper